In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE)

FEBS Letters

Volumn 580, Issue 14, 2006, Pages 3451-3456

  Monteiro, Filipe Almeida ^a,b   Cardoso, Isabel ^a   Sousa, Mónica Mendes ^a   Saraiva, Maria João ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

amyloid; Receptor for advanced glycation end products; Soluble RAGE; Transthyretin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; MUTANT PROTEIN; PREALBUMIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MICE; PREALBUMIN; RADIOLIGAND ASSAY; RATS; RECEPTORS, IMMUNOLOGIC; RECOMBINANT PROTEINS;

EID: 33646925693     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.05.020     Document Type: Article

References (37)

1. Coimbra A., and Andrade C. Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. I. Interstitial changes. Brain 94 (1971) 199-206
2. Coimbra A., and Andrade C. Familial amyloid polyneuropathy: an electron microscope study of the peripheral nerve in five cases. II. Nerve fibre changes. Brain 94 (1971) 207-212
3. Saraiva M.J. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 17 (2001) 493-503
4. Saraiva M.J., Birken S., Costa P.P., and Goodman D.S. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest. 74 (1984) 104-119
5. Raz A., Shiratori T., and Goodman D.S. Studies on the protein-protein and protein-ligand interactions involved in retinol transport in plasma. J. Biol. Chem. 245 (1970) 1903-1912
6. Schmidt A.M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267 (1992) 14987-14997
7. Neeper M., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267 (1992) 14998-15004
8. Hofmann M.A., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
9. Hori O., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
10. Sasaki N., et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci. Lett. 326 (2002) 117-120
11. Yan S.D., et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6 (2000) 643-651
12. Yan S.D., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
13. Huttunen H.J., Fages C., and Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274 (1999) 19919-19924
14. Kislinger T., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274 (1999) 31740-31749
15. Bucciarelli L.G., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 59 (2002) 1117-1128
16. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., Stern D., and Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4 (1998) 1025-1031
17. Goova M.T., et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159 (2001) 513-525
18. Taguchi A., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
19. Rong L.L., et al. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J. 18 (2004) 1812-1817
20. Sousa M.M., Yan S.D., Stern D., and Saraiva M.J. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab. Invest. 80 (2000) 1101-1110
21. Sousa M.M., Du Yan S., Fernandes R., Guimaraes A., Stern D., and Saraiva M.J. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21 (2001) 7576-7586
22. Srikrishna G., Huttunen H.J., Johansson L., Weigle B., Yamaguchi Y., Rauvala H., and Freeze H.H. N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem. 80 (2002) 998-1008
23. Almeida M.R., Damas A.M., Lans M.C., Brouwer A., and Saraiva M.J. Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6 (1997) 309-315
24. Bonifacio M.J., Sakaki Y., and Saraiva M.J. 'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Biochim. Biophys. Acta 1316 (1996) 35-42
25. Yeh C.H., et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50 (2001) 1495-1504
26. Valencia J.V., Weldon S.C., Quinn D., Kiers G.H., DeGroot J., TeKoppele J.M., and Hughes T.E. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 324 (2004) 68-78
27. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., and Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159 (2001) 1993-2000
28. Pepys M.B., et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA 91 (1994) 5602-5606
29. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108 (2001) 949-955
30. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., and Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
31. Sebastiao M.P., Saraiva M.J., and Damas A.M. The crystal structure of amyloidogenic Leu55 → Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J. Biol. Chem. 273 (1998) 24715-24722
32. Blake C.C., Geisow M.J., Swan I.D., Rerat C., and Rerat B. Structure of human plasma prealbumin at 2-5 Å resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J. Mol. Biol. 88 (1974) 1-12
33. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., and Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15 (2005) 16R-28R
34. Liliensiek B., et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
35. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., and Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62 (2002) 4805-4811
36. Chaney M.O., et al. RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim. Biophys. Acta 1741 (2005) 199-205
37. Monteiro F.A., Sousa M.M., Cardoso I., Amaral J.B., Guimaraes A., and Saraiva M.J. Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J. Neurochem. 97 (2006) 151-161